14 minutes ago
Beginning in 2021, the new crown virus is still spreading, and the vaccination that people expect is gradually spreading around the world. More than 2 million people in Israel have received a dose of the new crown vaccine, but there are still vaccinators infected with the virus. Hong Kong government officials said that they have not given up on the procurement of China Kexing vaccines and still await detailed data.
According to the latest data from Johns Hopkins University in the United States, there are more than 97 million new coronavirus infections worldwide and more than 2 million deaths.
Israelis diagnosed after being vaccinated
Israeli Army Radio quoted Israeli head of anti-epidemic work, Nachman Ash, as saying that the single-dose Pfizer/BioNtech vaccine does not seem to be as good as expected, nor is it as good as Pfizer claims.
Ash said that many people were infected with the new coronavirus between the first and second shots.
The Times of Israel reported that more than 2 million Israelis have received the first dose of Pfizer vaccine and more than 400,000 people have completed the second dose.
According to the Israeli Ministry of Health, more than 12,400 people have tested positive for the new crown virus after the vaccination, and 69 of them have completed the second dose.
People are still infected with the virus after being vaccinated, and the effectiveness of the vaccine is questioned. However, the British “Guardian” quoted the head of the Israeli Public Health Service (Sharon Alroy-Preis) as saying that in most cases, this is because the individual did not build enough antibodies after the vaccination and was subsequently exposed to the virus.
According to Pfizer, the effective rate of the vaccine jointly produced by it and the German company BioNTech is about 52% after the first dose of vaccination, and a few days after the second dose of vaccination, the effective rate will increase to about 95%.
The Israeli government stated on Thursday (January 21) that since Israel launched the world’s fastest vaccination campaign, Israel’s R value (a value indicating whether the pandemic is growing or shrinking) has fallen below 1 for the first time, which shows that The spread of the new coronavirus may have begun to fade.
Reuters reported that Israeli Deputy Health Minister Yoav Kisch attributed it to lockdown measures and vaccination, and said that without the more infectious British mutant virus, the drop would be even greater.
Israeli Prime Minister Netanyahu said that the vaccine would allow Israel to protect its most vulnerable groups and restart the economy next month.
Hong Kong: Did not give up the purchase of Kexing vaccine
The Hong Kong government announced earlier that it would purchase three vaccines: China Kexing, German BioNTech/Fosun, and British AstraZeneca/Oxford. On Thursday (January 21), the two scientific committees of the Centre for Health Protection of the Hong Kong Department of Health issued tentative consensus recommendations on the new crown vaccine vaccine. The two recommended vaccines are Fosun/BioNTech and Oxford/AstraZeneca vaccines. Including the Chinese Kexing vaccine announced by the Hong Kong government earlier, it has aroused concern about whether the Hong Kong government will not purchase Kexing vaccine.
In mid-January, Brazil announced data that the overall effective rate of the new coronavirus vaccine developed by China Kexing Biological was 50.4%. This figure barely meets the threshold required by global regulators, but it is far lower than the 78% previously announced by Brazil.
However, Chen Zhaoshi, director of the Hong Kong Food and Health Bureau, said in an interview with Hong Kong media that he has not given up on the procurement of Kexing vaccines, but Kexing has not provided detailed data for the time being. Regarding the effective data of Coxing vaccine released by Brazil, Chen Zhaoshi said that the research data of different countries are different and will wait for Coxing to provide the final report before making a decision.
She also pointed out that she was discussing procurement matters with the fourth vaccine supplier and could not disclose which supplier it was, but she indicated that it was not a vaccine developed by China National Pharmaceutical Group.
Zeng Haohui, a member of the Hong Kong Government’s Vaccination Program Task Force, said that the Vaccine Expert Committee is waiting for Kexing to provide the third phase clinical report data. If the data is not submitted as scheduled or the data fails, it may have to see if there are other options.